Welcome to our dedicated page for Danaher news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher stock.
Danaher Corporation reports developments tied to its global life sciences and diagnostics businesses, where its companies provide scientific technologies, clinical diagnostic systems and tools used in discovery, diagnosis and therapy development. Recurring updates include earnings calls, dividend actions, investor conference appearances and product or regulatory milestones from operating businesses such as Beckman Coulter Diagnostics.
Company news also covers diagnostic assays, immunoassay analyzer platforms, clinical-laboratory workflows and the Danaher Business System, which the company uses as an operating framework across its businesses. Additional recurring themes include shareholder voting matters, governance updates and capital-structure disclosures.
Danaher (DHR), through subsidiaries Integrated DNA Technologies (IDT) and Aldevron, launched co-developed research grade S.p. Cas9 mRNA in wild type and SpyFi™ high-fidelity formats for CRISPR-based genome editing workflows.
The offering combines IDT’s CRISPR engineering and guide RNA design expertise with Aldevron’s mRNA manufacturing capabilities, providing optimized constructs designed for high on-target editing, reduced off-target activity with SpyFi, low toxicity, and compatibility with multiple delivery methods including electroporation, cationic lipids, and lipid nanoparticles. The mRNA is enzymatically capped to offer a high-performing alternative to certain proprietary capping technologies and is positioned within a broader workflow that can progress from research grade to CGMP manufacturing, with additional co-developed base and prime editor products planned later.
Danaher (DHR)/b) declared a regular quarterly cash dividend of
Danaher (NYSE: DHR) appointed Julie Sawyer Montgomery as President, Chief Executive Officer, and Board member effective October 1, 2026, succeeding Rainer Blair, who will retire and serve as senior advisor until March 31, 2027 to support the leadership transition.
Since joining Danaher in 2017, Sawyer Montgomery has helped grow the Diagnostics platform from approximately $6.0 billion in revenue to about $11.0 billion, while approximately tripling operating profit. She led the acquisition of Masimo and the pending acquisition of StatLab and most recently served as Executive Vice President overseeing Diagnostics. Danaher also announced special equity incentive awards for key leaders and founders and confirmed there is no change to its previously communicated third-quarter and full-year 2026 guidance.
Danaher (NYSE: DHR) reported second quarter 2026 net earnings of $870 million, or $1.23 per diluted share, up 60% year-over-year. Non-GAAP adjusted diluted EPS rose 8% to $1.94. Revenue grew 5.5% to $6.3 billion, with non-GAAP core revenue up 3.0% and 4.5% excluding respiratory testing.
Operating cash flow was $1.5 billion and non-GAAP free cash flow $1.3 billion. Management cited a strong quarter in Life Sciences and mid-teens growth in bioprocessing orders, despite project timing effects on bioprocessing revenue. Danaher completed its Masimo acquisition earlier than anticipated and raised full-year 2026 adjusted EPS guidance to $8.45–$8.60, with expected non-GAAP core revenue growth of 3–4%.
Danaher (NYSE: DHR), through its operating company Leica Biosystems, has agreed to acquire StatLab Medical Products from private equity owners Audax Private Equity and Linden Capital Partners. The sale agreement is subject to customary closing conditions, and financial terms were not disclosed.
StatLab, founded in 1976 and headquartered in McKinney, Texas, manufactures pre-analytical products that support the full anatomic pathology workflow for pathology, histology, cytology and molecular diagnostics laboratories, as well as OEM customers, across the United States and Europe. Under Audax and Linden’s ownership, StatLab expanded from a primarily U.S.-focused supplier into a global integrated manufacturer, enhanced in-house production, built a dual-continent manufacturing footprint and completed nine strategic acquisitions to broaden its self-manufacturing capabilities. Linden reports approximately $14.0 billion of regulatory assets under management, while Audax Private Equity reports about $19.5 billion of assets under management as of January 2026.
The Danaher Foundation, supported by Danaher (NYSE:DHR), committed $1 million to support Ebola Bundibugyo outbreak response in the DRC and Uganda. Funds go to Save the Children, IRC and World Food Program USA for infection prevention, community health and food assistance.
Danaher (NYSE:DHR) will host its second quarter 2026 earnings conference call on July 21, 2026, starting at 8:00 a.m. ET for about one hour.
The call, slide presentation, replay, and earnings materials will be available in the website’s Investors section.
Masimo, a Danaher company (NYSE:DHR), received FDA 510(k) clearance for an AI-enabled opioid-induced respiratory depression (OIRD) detection feature on the Radius VSM wearable monitor.
Powered by the smartSET pulse oximetry platform, it analyzes continuous physiologic data and issues escalating visual alarms to help clinicians identify respiratory risk earlier in hospital patients on opioid therapy.
Danaher (NYSE:DHR) has completed its acquisition of Masimo, a specialty diagnostics provider focused on pulse oximetry and AI-enabled patient monitoring. Masimo becomes a wholly-owned subsidiary, will operate as a stand-alone company within Danaher’s Diagnostics segment, and its common stock has stopped trading on Nasdaq.
Danaher keeps previously communicated Q2 and full-year 2026 guidance ranges, excluding Masimo. The company does not expect a material Masimo contribution in Q2 2026 and plans to update full-year 2026 guidance with its second-quarter earnings release.
Sirius XM Holdings (NASD: SIRI) will join the S&P MidCap 400, replacing Masimo (NASD: MASI), effective before the market opens on June 11, 2026. Danaher (NYSE: DHR), an S&P 500 and 100 constituent, is acquiring Masimo, with the deal expected to close after final conditions.
On June 11, 2026, Sirius XM will be added to the index as a Communication Services company, while Masimo will be removed from the index’s Health Care sector.